证券代码：601567 证券简称：三星医疗 公告编号：临2025-065 担保对象及基本情况 | | 被担保人名称 | Nansen | Instrumentos | de Precision Mexico（以下简称"南森墨西哥"） | de | | --- | --- | --- | --- | --- | --- | | | 本次担保金额 | 500 | 万人民币 | | | | 担保对象 | 实际为其提供的担保余额 | 万元 0 | | | | | | 是否在前期预计额度内 | □是 | 否 | □不适用：_________ | | | | 本次担保是否有反担保 | □是 | 否 | □不适用：_________ | | 累计担保情况 | 对外担保逾期的累计金额（万元） | 0 | | --- | --- | | 截至本公告日上市公司及其控股 子公司对外担保总额（万元） | 974,850.00 | | 对外担保总额占上市公司最近一 期经审计净资产的比例（%） | 80.69% | | 特别风险提示（如有请勾选） | □对外担保总额超过最近一期经审计净资产 | | 100% | | | | 担保金 ...

宁波三星医疗电气股份有限公司 2025 年第二次临时股东会会议资料 宁波三星医疗电气股份有限公司 2025年第二次临时股东会会议资料 二〇二五年九月八日 | | | 宁波三星医疗电气股份有限公司 2025 年第二次临时股东会会议议程 时 间：2025 年 9 月 8 日 14:00 地 点：宁波市鄞州区首南街道日丽中路 757 号奥克斯中央大厦 25 楼会议室 主持人：沈国英董事长 议 程： 2 一、 主持人介绍到会股东、股东代表及代表股份数，宣布股东会开始； 二、 推举计票人、监票人，发放表决票； 三、 审议股东会议案： 1、 关于为全资子公司提供担保的议案 2、 关于公司取消监事会、修订《公司章程》并办理工商变更登记的议案 3、 关于修订部分内控制度的议案 4、 关于2025年半年度利润分配预案的议案 四、 参会股东及股东代表发言或提问； 五、 现场参会股东及股东代表对议案进行投票表决； 六、 收集表决票并计票； 七、 宣布现场投票及网络投票合并后的表决结果； 八、 见证律师宣读本次股东会法律意见书； 九、 宣读股东会决议，签署会议决议等相关文件； 十、 股东会闭幕。 宁波三星医疗电气股份有限公司 202 ...

证券代码：601567 证券简称：三星医疗 公告编号：临2025-068 宁波三星医疗电气股份有限公司 关于召开2025年第二次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一)股东会类型和届次 2025年第二次临时股东会 (二)股东会召集人：董事会 (三)投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合的方 式 东会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过互联网 投票平台的投票时间为股东会召开当日的 9:15-15:00。 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 9 月 8 日 14 点 00 分 召开地点：宁波市鄞州区首南街道日丽中路 757 号奥克斯中央大厦 25 楼会 议室 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 9 月 8 日 至2025 年 9 月 8 日 采用上海证券 ...

经审核，监事会认为董事会编制和审议《三星医疗 2025 年半年度报告》及 其摘要的程序符合法律、行政法规及中国证监会的规定，报告内容真实、准确、 完整地反映了公司 2025 年半年度的经营管理情况，不存在任何虚假记载、误导 性陈述或者重大遗漏。 详见公司披露于上海证券交易所网站（www.sse.com.cn）的《三星医疗 2025 年半年度报告》及报告摘要。 表决结果：3 票赞成、0 票反对、0 票弃权。 证券代码：601567 证券简称：三星医疗 公告编号：临 2025-064 宁波三星医疗电气股份有限公司 第六届监事会第二十次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 宁波三星医疗电气股份有限公司（以下简称"公司"）于 2025 年 8 月 11 日 通过书面方式发出召开第六届监事会第二十次会议通知，会议于 2025 年 8 月 21 日在公司会议室以现场结合通讯方式召开。本次会议应到监事 3 人，实到监事 3 人。会议由监事会主席郑伟科先生主持，会议的召集和召开符合《中华人民共和 国公司法》和《宁波三星 ...

宁波三星医疗电气股份有限公司 第六届董事会第二十五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：601567 证券简称：三星医疗 公告编号：临 2025-063 宁波三星医疗电气股份有限公司（以下简称"公司"）于 2025 年 8 月 11 日以 书面方式发出召开第六届董事会第二十五次会议的通知，会议于 2025 年 8 月 21 日在公司会议室以现场结合通讯方式召开。本次会议应到董事 9 人，实到董事 9 人。会议由董事长沈国英女士主持，公司监事和其他高级管理人员列席了会议。 会议的召集和召开符合《中华人民共和国公司法》和《宁波三星医疗电气股份有 限公司章程》等法律、法规及规范性文件的有关规定。经与会董事认真审议并表 决，通过了以下议案，形成决议如下： 一、审议通过了关于 2025 年半年度报告及其摘要的议案 详见公司披露于上海证券交易所网站（www.sse.com.cn）的《三星医疗 2025 年半年度报告》及报告摘要。 表决结果：9 票赞成、0 票反对、0 票弃权。 该议案已经公司审计委员会审 ...

Dividend Distribution - The company plans to distribute a cash dividend of RMB 4.85 per 10 shares, totaling approximately RMB 678.76 million, which represents 55.20% of the net profit attributable to shareholders for the first half of 2025[6]. - The company aims to maintain a cash dividend payout ratio of no less than 45% annually from 2025 to 2027, sharing the development results with shareholders[85]. - The company maintained a cash dividend policy, emphasizing stable and continuous returns to shareholders[84]. - In the first half of 2025, the company approved a cash dividend distribution plan of 8.90 CNY (including tax) per 10 shares, totaling approximately 1.246 billion CNY, which accounts for 55.12% of the net profit attributable to shareholders for the fiscal year 2024[85]. - On August 21, 2025, the company proposed a cash dividend of 4.85 CNY (including tax) per 10 shares for the first half of 2025, estimated to distribute around 678.8 million CNY, representing 55.20% of the net profit attributable to shareholders for that period[86]. Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB, representing a year-over-year growth of 15%[16]. - The company's operating revenue for the first half of the year reached ¥7,972,213,807.13, representing a year-on-year increase of 13.93% compared to ¥6,997,465,533.74 in the same period last year[23]. - The total profit for the reporting period was ¥1,401,225,534.45, which is a 3.13% increase from ¥1,358,643,633.59 in the previous year[24]. - The net profit attributable to shareholders was ¥1,229,732,476.50, reflecting a growth of 6.93% compared to ¥1,150,008,819.85 in the same period last year[24]. - The company achieved a revenue of 7.972 billion yuan, a year-on-year increase of 13.93%, and a net profit attributable to shareholders of 1.230 billion yuan, up 6.93%[49]. Risk Management - The company has detailed potential risks in the management discussion and analysis section of the report[8]. - The report includes a forward-looking statement risk disclaimer, indicating that future plans do not constitute a commitment to investors[7]. - The company emphasizes the importance of reviewing the detailed risk descriptions provided in the report[8]. - The board of directors and management confirm the accuracy and completeness of the financial report, ensuring no significant omissions or misleading statements[3][5]. - There are no non-operational fund occupations by controlling shareholders or related parties[8]. Market Expansion and Strategy - The company is expanding its market presence by entering two new provinces, aiming for a 5% market share in these regions within the next year[16]. - A strategic acquisition of a local competitor was completed, which is anticipated to enhance the company's market position and increase revenue by 8%[16]. - The company has established partnerships with three new healthcare providers to expand its service offerings[16]. - The company is actively expanding its presence in key regions such as the Yangtze River Delta and the Pearl River Delta, focusing on high-quality rehabilitation services[46]. - The company is focusing on expanding its overseas market presence while enhancing its brand's international influence[81]. Research and Development - Research and development expenses increased by 25%, reflecting the company's commitment to innovation and technology advancement[16]. - The company invested 257 million RMB in R&D, accounting for 3.22% of consolidated operating revenue, to enhance its R&D capabilities and core competitiveness[83]. - The company has established four R&D centers and has been certified with CMMI V2.0 L5, indicating its strong research and innovation capabilities[59]. - The company has obtained 32 automation patents over the past three years, continuing to advance its "smart manufacturing" strategy[61]. - The company has developed a differentiated rehabilitation medical system, becoming a leading institution in rehabilitation medicine in China[64]. Financial Position and Assets - The company's total assets decreased by 5.02% to ¥23,246,567,450.35 from ¥24,476,486,586.93 at the end of the previous year[24]. - The company's total assets at the end of the reporting period were approximately ¥12.27 billion, indicating a stable asset base[150]. - The company's total liabilities decreased to ¥10,836,499,605.11 as of June 30, 2025, from ¥12,202,548,432.10 at the end of 2024, a decrease of about 11.2%[132]. - The total equity increased to ¥12,410,067,845.24 as of June 30, 2025, compared to ¥12,273,938,154.83 on December 31, 2024, reflecting an increase of approximately 1.1%[132]. - The company’s total liabilities and equity reflect a stable financial position, indicating ongoing operational capacity[168]. Corporate Governance - The board meeting was attended by all directors, ensuring collective responsibility for the report's content[4]. - The report has not been audited, and the management has declared the financial report's authenticity[5]. - The company has enhanced its information disclosure quality, actively reporting on orders, bids, and contracts to meet investor needs and regulatory requirements[86]. - The financial statements were approved by the board of directors on August 21, 2025, ensuring compliance with regulatory standards[166]. - The company adheres to the enterprise accounting standards, ensuring that financial statements accurately reflect its financial position and operating results[170]. Operational Efficiency - The company’s expense ratio for the first half of 2025 was 13.65%, a decrease of 3.92 percentage points year-on-year, reflecting improved operational efficiency[53]. - The company plans to enhance its supply chain efficiency, targeting a reduction in operational costs by 10% over the next fiscal year[16]. - The company is engaged in ongoing efforts to enhance its operational efficiency and market presence through strategic workforce integration[94]. - The company is enhancing its operational management through technological innovation and service model restructuring in response to deepening medical insurance payment reforms[39]. - The company has established a digital management system to mitigate operational risks associated with its expanding scale[81]. Compliance and Social Responsibility - The company is actively responding to national policies on common prosperity and corporate social responsibility[94]. - The company has included three subsidiaries in the list of enterprises required to disclose environmental information[93]. - The company has improved its ESG rating to AA, positioning it among the top in the industry, as part of its commitment to sustainable development[87]. - The company has made commitments regarding non-competition and profit forecasts, including a net profit target of no less than 47.5 million yuan for the 2023-2025 period[96]. - The company has outlined specific measures to ensure compliance with performance commitments and compensation obligations[97].

证券代码：601567 证券简称：三星医疗 公告编号：临 2025-067 宁波三星医疗电气股份有限公司 关于2025年半年度利润分配预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、利润分配预案内容 （一）利润分配预案的具体内容 截至2025年6月30日，宁波三星医疗电气股份有限公司（以下简称"公司"）母 公司期末未分配利润为人民币1,592,268,983.80元。经公司第六届董事会第二十五次会 议、第六届监事会第二十次会议审议通过，公司2025年半年度拟以实施权益分派股权 登记日登记的总股本（扣除回购专用账户的股份）为基数进行现金分红。本次利润分 配预案如下： 公司拟以本次实施权益分派股权登记日登记的总股本（扣除回购专用账户的股份） 为基数，向股东每10股派发现金红利（含税）4.85元。截至本公告披露日，公司总股 本为1,405,251,200股，扣除回购专用账户股份5,755,371股，公司可参与利润分配的总 股数为1,399,495,829股，以此计算预计合计派发现金红利约人民币678, ...

每经AI快讯，三星医疗（SH 601567，收盘价：24.66元）8月21日晚间发布公告称，公司第六届第二十 五次董事会会议于2025年8月21日在公司会议室以现场结合通讯方式召开。会议审议了《关于2025年半 年度报告及其摘要的议案》等文件。 2024年1至12月份，三星医疗的营业收入构成为：制造业占比76.16%，医疗业占比22.31%，其他业务占 比1.48%，金融业占比0.04%。 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 截至发稿，三星医疗市值为347亿元。 每经头条（nbdtoutiao）——最火游资不再是方新侠、章盟主、佛山无影脚？这名95后声名鹊起！ （记者 曾健辉） ...

Group 1 - Samsung Medical reported a revenue of approximately 7.972 billion yuan for the first half of 2025, representing a year-on-year increase of 13.93% [1] - The net profit attributable to shareholders of the listed company was approximately 1.23 billion yuan, showing a year-on-year increase of 6.93% [1] - Basic earnings per share were 0.87 yuan, reflecting a year-on-year increase of 7.41% [1] Group 2 - As of the report date, Samsung Medical's market capitalization stood at 34.7 billion yuan [2]

每经AI快讯，8月21日，三星医疗(601567.SH)发布2025年半年度报告，公司2025年上半年实现营业收入 79.72亿元，同比增长13.93%；实现归属于上市公司股东的净利润12.30亿元，同比增长6.93%。公司拟 向股东每10股派发现金红利4.85元（含税）。 ...